Skip to main navigation Skip to search Skip to main content

Central serous chorioretinopathy treatment with a systemic PDE5 and PDE6 inhibitor (sildenafil)

  • D. Jackson Coleman
  • , Winston Lee
  • , Suzanne Daly
  • , Mark P. Breazzano
  • , Janet Sparrow
  • , Stephen H. Tsang

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: Examine the use of systemic phosphodiesterase inhibition (sildenafil) to clear central serous chorioretinopathy (CSCR). Observations: In a long-standing CSCR patient, sildenafil produced a rapid resolution. When discontinued (dechallenge) the CSCR returned. When rechallenged, the CSCR again rapidly disappeared and did not recur in 5 months of continued therapy. Conclusions: AND IMPORTANCE: Systemic sildenafil can cause rapid clearance of CSCR and can augment or replace other treatments.

Original languageEnglish (US)
Article number100998
JournalAmerican Journal of Ophthalmology Case Reports
Volume21
DOIs
StatePublished - Mar 2021
Externally publishedYes

Keywords

  • Central serous chorioretinopathy
  • PDE5/6 inhibitor
  • Sildenafil

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint

Dive into the research topics of 'Central serous chorioretinopathy treatment with a systemic PDE5 and PDE6 inhibitor (sildenafil)'. Together they form a unique fingerprint.

Cite this